Analysis of rare mutations in non-small cell lung cancer patients
Official title: Molecular Landscape Analysis and Clinical and Therapeutic Implications for NSCLC Patients With Rare Mutations
Run by Shanghai Chest Hospital · NCT05701787 · Data updated 2026-11-12
This study looks at rare genetic changes in people with non-small cell lung cancer to see if understanding these changes can lead to better treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Shanghai Chest Hospital Academic / other |
| Locations | 2 sites (Shanghai, Shanghai Municipality and 1 other locations) |
| Status | Recruiting |
| Started | January 1, 2019 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2029 |
| Registry record updated | May 22, 2025 |
| Trial ID | NCT05701787 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with histologically confirmed NSCLC and specific rare mutations.
✕Probably not a fit
Patients without rare mutations in NSCLC or those under 18 years of age may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients with non-small cell lung cancer (NSCLC) who have rare mutations. It aims to analyze the molecular landscape of these mutations and their clinical implications, utilizing next-generation sequencing (NGS) to identify potential targeted therapies. By understanding the diverse mutations present in NSCLC, the study seeks to address the unmet need for effective treatment options tailored to these specific genetic profiles. The findings could help improve treatment strategies and patient outcomes in this population.
Why it matters
Potential benefit: If successful, this study could lead to more effective targeted therapies for NSCLC patients with rare mutations, improving their quality of life and survival rates.
How similar studies have gone: Other studies have shown success in targeting specific mutations in NSCLC, indicating that this approach has potential for meaningful advancements in treatment.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically proven diagnosis of NSCLC with rare mutations including EGFR rare mutations, ALK fusion, ROS1 fusion, BRAF V600E, cMET exon 14 skipping, KRAS G12C, RET fusion, NTRK fusion, etc. * 18 years of age or older * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * None
Where it's running
-
Xiaomin Niu
Shanghai, Shanghai Municipality, China Recruiting -
Xiaomin Niu
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Principal investigator: Xiaomin Niu — Shanghai Chest Hospital
- Study coordinator: Xiaomin Niu
- Email: ar_tey@hotmail.com
- Phone: 021-22200000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating a new CAR T-cell therapy for solid tumors expressing MSLN
This study is testing a new CAR T-cell therapy to see if it can safely treat adults with solid tumors like colorectal and lung cancer that express a specific protein.
-
Targeted radiation therapy for advanced lung cancer
This study is testing if adding a special type of radiation therapy to regular drug treatment can help people with advanced lung cancer that has spread to the liver feel better and live longer.
-
Using patient-derived tumoroids to predict response to immunotherapy in lung cancer
This study is testing if lab-grown mini tumors from lung cancer patients can help doctors figure out who will benefit from a new type of immune therapy.
-
Combining Atezolizumab and Pirfenidone for Advanced Lung Cancer
This study is testing if adding pirfenidone to atezolizumab can help people with advanced lung cancer who have already been treated feel better and fight their cancer more effectively.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.